Unnamed: 0,title,date,stock,sentiment
1112944.0,Sage Therapeutics shares are trading higher after RBC Capital reiterates an Outperform and raised the price target from $72 to $75 per share.,2020-05-26 09:31:00-04:00,SAGE,positive
1112945.0,"RBC Capital Reiterates Outperform on Sage Therapeutics, Raises Price Target to $75",2020-05-26 07:20:00-04:00,SAGE,neutral
1112946.0,"Wedbush Downgrades Sage Therapeutics to Neutral, Raises Price Target of $37",2020-05-08 13:13:00-04:00,SAGE,neutral
1112947.0,"SunTrust Robinson Humphrey Maintains Hold on Sage Therapeutics, Lowers Price Target to $35",2020-05-08 11:26:00-04:00,SAGE,negative
1112948.0,"RBC Capital Maintains Outperform on Sage Therapeutics, Raises Price Target to $72",2020-05-08 09:39:00-04:00,SAGE,neutral
1112949.0,"Sage Therapeutics Q1 EPS $(2.440) Beats $(3.140) Estimate, Sales $2.300M Miss $2.800M Estimate",2020-05-07 16:11:00-04:00,SAGE,negative
1112950.0,"RBC Capital Maintains Outperform on Sage Therapeutics, Raises Price Target to $71",2020-04-28 08:07:00-04:00,SAGE,neutral
1112951.0,"SunTrust Robinson Humphrey Maintains Hold on Sage Therapeutics, Lowers Price Target to $37",2020-04-09 12:25:00-04:00,SAGE,negative
1112952.0,"BMO Capital Maintains Outperform on Sage Therapeutics, Lowers Price Target to $65",2020-04-09 11:12:00-04:00,SAGE,negative
1112953.0,"Canaccord Genuity Maintains Buy on Sage Therapeutics, Lowers Price Target to $80",2020-04-08 12:05:00-04:00,SAGE,negative
1112954.0,"Citigroup Maintains Buy on Sage Therapeutics, Raises Price Target to $54",2020-04-08 11:09:00-04:00,SAGE,neutral
1112955.0,"RBC Capital Maintains Outperform on Sage Therapeutics, Raises Price Target to $68",2020-04-08 10:27:00-04:00,SAGE,neutral
1112956.0,"Mizuho Maintains Neutral on Sage Therapeutics, Lowers Price Target to $36",2020-04-08 09:33:00-04:00,SAGE,negative
1112957.0,"Oppenheimer Maintains Outperform on Sage Therapeutics, Lowers Price Target to $50",2020-04-08 08:07:00-04:00,SAGE,negative
1112958.0,Guggenheim Downgrades Sage Therapeutics to Neutral,2020-04-08 07:02:00-04:00,SAGE,neutral
1112959.0,"Sage Says Current Cash Balance, Marketable Securities Should Support Operations Into 2022",2020-04-07 16:02:00-04:00,SAGE,positive
1112960.0,"Sage Therapeutics Reports Restructuring, Sees Annualized Cost Savings ~$170M, Will Cut 340 Employees From Headcount, ~53% Of Workforce",2020-04-07 16:01:00-04:00,SAGE,negative
1112961.0,"SunTrust Robinson Humphrey Maintains Hold on Sage Therapeutics, Lowers Price Target to $40",2020-03-26 09:23:00-04:00,SAGE,negative
1112962.0,Sage Therapeutics Announces Development Plan For Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting With FDA,2020-03-18 06:31:00-04:00,SAGE,neutral
1112963.0,"RBC Capital Upgrades Sage Therapeutics to Outperform, Lowers Price Target to $60",2020-03-18 06:28:00-04:00,SAGE,negative
1112964.0,"Citigroup Initiates Coverage On Sage Therapeutics with Buy Rating, Announces $71 Price Target",2020-03-06 05:06:00-05:00,SAGE,neutral
1112965.0,"Morgan Stanley Maintains Overweight on Sage Therapeutics, Lowers Price Target to $117",2020-03-03 08:18:00-05:00,SAGE,negative
1112966.0,"SunTrust Robinson Humphrey Maintains Hold on Sage Therapeutics, Lowers Price Target to $50",2020-02-28 09:20:00-05:00,SAGE,negative
1112967.0,"H.C. Wainwright Maintains Neutral on Sage Therapeutics, Lowers Price Target to $78",2020-02-28 07:35:00-05:00,SAGE,negative
1112968.0,"Mizuho Maintains Neutral on Sage Therapeutics, Lowers Price Target to $58",2020-02-28 07:24:00-05:00,SAGE,negative
1112969.0,Sage Therapeutics shares are trading lower after the company reported worse-than-expected Q4 sales results.,2020-02-27 09:27:00-05:00,SAGE,neutral
1112970.0,"Sage Therapeutics Sees ZULRESSO Sales Growth 'Modest' Over Next Couple Qtrs., Sees Growth In Sales During H2'20",2020-02-27 06:38:00-05:00,SAGE,positive
1112971.0,"Sage Therapeutics Q4 EPS $(3.25) Beats $(3.61) Estimate, Sales $1.96M Miss $3.68M Estimate",2020-02-27 06:37:00-05:00,SAGE,negative
1112972.0,"Mizuho Initiates Coverage On Sage Therapeutics with Neutral Rating, Announces $69 Price Target",2020-02-06 05:19:00-05:00,SAGE,neutral
1112973.0,"Mizuho Initiates Coverage On Pfizer, Evolus, Karuna Therapeutics With Buy Ratings, Neurocrine Biosciences, Sage Therapeutics With Neutrals",2020-02-05 16:48:00-05:00,SAGE,neutral
1112974.0,Watching Sage Therapeutics Shares As Traders Circulate Notice From ClinicalTrials.gov Showing Recruitment Status For Co.'s SAGE-217 Treatment For Major Depressive Disorder Suspended,2019-12-23 09:53:00-05:00,SAGE,negative
1112975.0,Sage Therapeutics Says Plans To Advance SAGE-718 For Huntington's Disease,2019-12-10 07:37:00-05:00,SAGE,neutral
1112976.0,"SunTrust Robinson Humphrey Downgrades Sage Therapeutics to Hold, Lowers Price Target to $70",2019-12-06 10:55:00-05:00,SAGE,negative
1112977.0,Ladenburg Thalmann Downgrades Sage Therapeutics to Neutral,2019-12-06 09:48:00-05:00,SAGE,neutral
1112978.0,"JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to $105",2019-12-06 09:42:00-05:00,SAGE,negative
1112979.0,"Morgan Stanley Maintains Overweight on Sage Therapeutics, Lowers Price Target to $125",2019-12-06 08:26:00-05:00,SAGE,negative
1112980.0,Sage Therapeutics shares are trading higher after SVB Leerink upgraded the stock from Underperform to Market Perform.,2019-12-06 08:20:00-05:00,SAGE,positive
1112981.0,SVB Leerink Upgrades Sage Therapeutics to Market Perform,2019-12-06 06:29:00-05:00,SAGE,neutral
1112982.0,Hearing Suntrust Downgraded Sage Therapeutics To Hold; Unconfirmed,2019-12-05 12:58:00-05:00,SAGE,negative
1112983.0,"Sage Therapeutics Shares Resume Trade, Down 56%",2019-12-05 09:53:00-05:00,SAGE,positive
1112984.0,Sage Therapeutics shares trading lower following news topline results from a Phase 3 study of SAGE-217 did not meet a primary endpoint at day 15 of the trial.,2019-12-05 07:22:00-05:00,SAGE,neutral
1112985.0,Sage Therapeutics Reports Topline Results From Pivotal Phase 3 MOUNTAIN Study Of SAGE-217 In Major Depressive Disorder Did Not Meet Primary Endpoint At Day 15,2019-12-05 06:31:00-05:00,SAGE,negative
1112986.0,"Canaccord Genuity Maintains Buy on Sage Therapeutics, Lowers Price Target to $218",2019-11-13 08:59:00-05:00,SAGE,negative
1112987.0,"Sage Therapeutics Q3 EPS $(3.48) Misses $(3.36) Estimate, Sales $3.57M Miss $3.6M Estimate",2019-11-12 06:44:00-05:00,SAGE,negative
1112988.0,"H.C. Wainwright Initiates Coverage On Sage Therapeutics with Neutral Rating, Announces $160 Price Target",2019-10-30 07:11:00-04:00,SAGE,neutral
1112989.0,Sage Therapeutics Highlights New England Journal Of Medicine Published Data From Phase 2 Trial With SAGE-217 For Major Depressive Disorder,2019-09-04 17:06:00-04:00,SAGE,negative
1112990.0,Sage Therapeutics Q2 EPS $(3.28) Beats $(3.33) Estimate,2019-08-06 06:37:00-04:00,SAGE,neutral
1112991.0,UPDATE: Sage Says 'Data from Phase 1 study with SAGE-324 show activity in essential tremor; differentiated profile opens potential pathways for development in additional neurological indications',2019-07-24 06:32:00-04:00,SAGE,neutral
1112992.0,Sage Therapeutics Reports Data From Phase 2 Open-Label Study Of SAGE-217 For Bipolar Depression Showed 'demonstrate rapid improvement compared to baseline',2019-07-24 06:31:00-04:00,SAGE,negative
1112993.0,Sage Therapeutics shares are trading higher after Stifel reiterated a Buy rating and said they expect SAGE-217 to show signs of efficacy in bipolar depression. Analysts said the upcoming July pipeline update may represent an 'incremental positive.',2019-07-09 13:12:00-04:00,SAGE,negative
1112994.0,"Ligand Pharmaceuticals Highlights Launch Of Sage Therapeutics' ZULRESSO, Which Utilizes Ligand's Captisol",2019-07-01 09:12:00-04:00,SAGE,neutral
1112995.0,Sage Therapeutics Announces US Drug Enforcement Administration Scheduling of ZULRESSO Injection ; On Track For Full US Commercial Launch In Late June,2019-06-14 08:54:00-04:00,SAGE,neutral
1112996.0,"Wedbush Initiates Coverage On Sage Therapeutics, Inc. - Common Stock with Outperform Rating, Announces $207 Price Target",2019-05-23 08:04:00-04:00,SAGE,neutral
1112997.0,"Raymond James Reinstates Market Perform on Sage Therapeutics, Inc. - Common Stock",2019-04-26 08:32:00-04:00,SAGE,neutral
1112998.0,"Jefferies Initiates Coverage On Sage Therapeutics, Inc. - Common Stock with Buy Rating, Announces $195 Price Target",2019-04-25 09:09:00-04:00,SAGE,neutral
1112999.0,"Jefferies Initiates Coverage On Sage Therapeutics, Inc. - Common Stock with Buy Rating",2019-04-25 07:21:00-04:00,SAGE,neutral
1113000.0,Hearing Dealreporter Says Biogen May Be Targeting Sage Therapeutics,2019-04-04 11:22:00-04:00,SAGE,neutral
1113001.0,"Alkermes, Merck, Sage Therapeutics and Takeda Pharma Announce a Partnership to Qualify Biomarkers for Schizophrenia Drug Development",2019-04-01 07:07:00-04:00,SAGE,neutral
1113002.0,Ligand Pharma Reports Will Receive $3M Milestone Payment Related To FDA Approval Of Sage Therapeutics' ZULRESSO Injection For Treatment Of PPD,2019-03-21 09:03:00-04:00,SAGE,positive
1113003.0,Sage Therapeutics Earlier Announced Pricing Of $500M Common Stock Offering At $150/Share,2019-02-26 09:38:00-05:00,SAGE,neutral
1113004.0,Sage Therapeutics shares are trading lower after the company announced a $500 million stock offering priced at $150 per share.,2019-02-26 08:37:00-05:00,SAGE,positive
1113005.0,Sage Therapeutics shares are trading lower after the company announced a $500 million common stock offering.,2019-02-25 16:47:00-05:00,SAGE,neutral
1113006.0,Sage Therapeutics Reports Offering OF $500M Common Stock Offering,2019-02-25 16:01:00-05:00,SAGE,neutral
1113007.0,"Guggenheim Initiates Coverage On Sage Therapeutics with Buy Rating, Announces $205 Price Target",2019-02-22 09:43:00-05:00,SAGE,neutral
1113008.0,"Sage Therapeutics Q4 EPS $(3.38) Misses $(2.91) Estimate, Sales $273K",2019-02-19 06:37:00-05:00,SAGE,negative
1113009.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Tue., Jan. 8, 2019",2019-01-08 10:58:00-05:00,SAGE,positive
1113010.0,Sage Therapeutics' shares are trading higher after SAGE-217 met its primary and secondary endpoints in its Phase 3 clinical trial for postpartum depression.,2019-01-07 07:52:00-05:00,SAGE,negative
1113011.0,Sage Therapeutics' SAGE-217 Met its Primary and Secondary Endpoints in its Phase 3 Clinical Trial in Postpartum Depression,2019-01-07 06:07:00-05:00,SAGE,negative
1113012.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018",2018-12-19 12:43:00-05:00,SAGE,negative
1113013.0,"Morgan Stanley Maintains Overweight on Sage Therapeutics, Lowers Price Target to $213",2018-12-19 07:55:00-05:00,SAGE,negative
1113014.0,"Sage Therapeutics Filing Shows Registration For Mixed Securities Offering, No Size Disclosed",2018-12-18 16:42:00-05:00,SAGE,neutral
1113015.0,"Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018",2018-12-10 11:01:00-05:00,SAGE,negative
1113016.0,"Sage Therapeutics Reports Received Notification Of PDUFA Extension For ZULRESSO Injection From Dec. 19, 2018 To Mar. 19, 2019",2018-11-20 07:32:00-05:00,SAGE,neutral
1113017.0,"Leerink Swann Initiates Coverage On Sage Therapeutics with Underperform Rating, Announces $80 Price Target",2018-11-15 09:20:00-05:00,SAGE,neutral
1113018.0,"Leerink Swann Initiates Coverage On Sage Therapeutics with Underperform Rating, Announces $80 Price Target",2018-11-13 08:38:00-05:00,SAGE,neutral
1113019.0,Sage Therapeutics Q3 EPS $(2.63) Misses $(2.42) Estimate,2018-11-06 06:39:00-05:00,SAGE,negative
1113020.0,"RBC Capital Maintains Outperform on Sage Therapeutics, Raises Price Target to $261",2018-11-05 11:39:00-05:00,SAGE,neutral
1113021.0,"Canaccord Reiterates Buy, $220 Price Target On Sage Therapeutics; Says Phase 3 Top-Line Data For Oral SAGE-217 In Postpartum Depression Will Serve As A Big Catalyst In Q4",2018-11-05 08:43:00-05:00,SAGE,negative
1113022.0,Sage Therapeutics Press Release Confirms FDA AdCom Metting Votes 17-1 In Support Of ZULRESSO (Brexanolone)'s Safety,2018-11-02 16:46:00-04:00,SAGE,positive
1113023.0,"US FDA Panel Votes In Favor Of Sage Therapeutics' Treatment For Postpartum Depression, Says Benefits Of Drug Outweigh Risks",2018-11-02 15:33:00-04:00,SAGE,negative
1113024.0,"Hearing AdCom Panel Voted 16-2 In Favor Of Safety For Sage Therapeutics' ZULRESSO, Unconfirmed",2018-11-02 14:31:00-04:00,SAGE,positive
1113025.0,Sage Therapeutics Reports Shares Halted For AdCom Meeting On ZULRESSO Injection For Treatment Of Postpartum Depression; BZ NOTE: Expect Sage Shares To Be Halted For Most Of Friday's Intraday Session,2018-11-02 07:06:00-04:00,SAGE,positive
1113026.0,Sage Therapeutics Shares Halted News Pending,2018-11-02 07:01:00-04:00,SAGE,positive
1113027.0,"Morgan Stanley Maintains Overweight on Sage Therapeutics, Raises Price Target to $230",2018-10-11 10:00:00-04:00,SAGE,negative
1113028.0,"Hearing Oppenheimer Initiated Sage Therapeutics With Outperform Rating, $170 Price Target",2018-10-10 16:29:00-04:00,SAGE,neutral
1113029.0,Stifel Transfers Coverage Of Sage Therapeutics With A Buy And $239 Price Target,2018-08-07 08:23:00-04:00,SAGE,neutral
1113030.0,"Sage Therapeutics Q2 EPS $(0.36) Beats $(1.89) Estimate, Sales $90M",2018-08-07 06:39:00-04:00,SAGE,neutral
1113031.0,"PiperJaffray Initiates Coverage On Sage Therapeutics with Overweight Rating, Announces $206 Price Target",2018-08-06 08:53:00-04:00,SAGE,negative
1113032.0,"Morgan Stanley Maintains Overweight on Sage Therapeutics, Raises Price Target to $228",2018-07-13 07:55:00-04:00,SAGE,negative
1113033.0,"Sage Therapeutics, Shionogi Enter Strategic Collaboration to Develop and Commercialize SAGE-217 for MDD and Other Indications in Japan, Taiwan, S. Korea",2018-06-13 20:35:00-04:00,SAGE,neutral
1113034.0,"Canaccord Genuity Maintains Buy on Sage Therapeutics, Raises Price Target to $220",2018-06-13 07:41:00-04:00,SAGE,neutral
1113035.0,Sage Announces Pivotal Phase 3 Trial Status For SAGE-217 in Major Depressive Disorder And Postpartum Depression Based On FDA Breakthrough Therapy Meeting,2018-06-12 06:30:00-04:00,SAGE,negative
1113036.0,"Ladenburg Thalmann Initiates Coverage On Sage Therapeutics with Buy Rating, Announces $230 Price Target",2018-06-06 07:39:00-04:00,SAGE,neutral
1113037.0,Sage Therapeutics Q1 EPS $(1.68) Beats $(1.84) Estimate,2018-05-03 06:41:00-04:00,SAGE,neutral
1113038.0,Sage Therapeutics Submits New Drug Application to the US FDA for Intravenous Brexanolone in the Treatment of Postpartum Depression,2018-04-23 07:01:00-04:00,SAGE,negative
1113039.0,"'$SAGE spox to me:

""Yes, we cancelled participation in the JPMorgan meeting in Napa due to some travel logistics issues – just flight schedule complications.""'-STAT's Adam Feuerstein",2018-04-10 15:16:00-04:00,SAGE,negative
1113040.0,Traders Circulating Social Media Chatter That Sage Therapeutics Cancelled Out Of Upcoming Conference Due To A Scheduling Conflict,2018-04-10 14:44:00-04:00,SAGE,negative
1113041.0,"UPDATE: Sage Therapeutics Shares Spike, Seeing Vauge Social Media Mention Of Rumors Co. Cancelled A Conference Presentation, Unconfirmed",2018-04-10 14:40:00-04:00,SAGE,negative
1113042.0,"Sage Therapeutics Shares Up ~20%, Not Seeing Any Notable News Item Yet",2018-04-10 14:39:00-04:00,SAGE,positive
1113043.0,"Morgan Stanley Initiates Coverage On Sage Therapeutics with Overweight Rating, Announces $225.00 Price Target",2018-02-26 07:15:00-05:00,SAGE,negative
1113044.0,Sage Therapeutics Reports Q4 EPS $(1.75) vs $(1.99) Est.,2018-02-22 06:35:00-05:00,SAGE,neutral
1113045.0,"Leerink Partners Global Healthcare Conference Begins Today, Presenters Include: Dova Pharma, Heron Therapeutics, Sage Therapeutics, Enanta, The Medicines Company, Puma Biotech, Dicerna Pharma, Biogen, bluebird bio, and Alexion Pharma",2018-02-14 07:06:00-05:00,SAGE,neutral
1113046.0,Sage Therapeutics Announces $575M Common Stock Offering,2018-02-07 16:01:00-05:00,SAGE,neutral
1113047.0,Sage Therapeutics Grated Breakthrough Designation by the FDA for SAGE-217,2018-02-07 06:32:00-05:00,SAGE,neutral
1113048.0,Sage Therapeutics To Give Pipeline Update At JPM Conf. And Outline Key Initiates For 2018,2018-01-08 13:04:00-05:00,SAGE,neutral
1113049.0,"SAGE Thearpeutics Shares Down 6% Mon.; Co. Earlier Issued Release Highlighting Will Offer Update On Pipeline, Outline Key '18 Initiatives at JP Morgan Healthcare Conference",2018-01-08 11:46:00-05:00,SAGE,positive
1113050.0,"BMO Continues Sell-Side Trend Of Price Target Raise In Sage Therapeutics, Ups Target To $203 As Firm Says Phase 2 MDD Data 'Points To SAGE-217 As Best-In Class Drug'",2017-12-08 10:18:00-05:00,SAGE,neutral
1113051.0,Cowen Raises Sage Therapeutics Price Target To $202 On Derisked Potential In MDD,2017-12-07 13:47:00-05:00,SAGE,neutral
1113052.0,SunTrust Raises Sage Price Traget From $116 To $178 On Positive Phase 2 Data In MDD,2017-12-07 13:36:00-05:00,SAGE,positive
1113053.0,"Marinus Pharmaceuticals Shares Up 16.64% On 2x Avg. Volume, Perhaps In Sympathy With Sage Therapeutics After It's Positive Phase 2 Results; Both Develop Neuropsychiatric Disorder Treatments",2017-12-07 10:39:00-05:00,SAGE,positive
1113054.0,Adam Feuerstein Tweets: Jeff Jonas is doing a great job as $SAGE CEO but let's pump the brakes a bit on naming him Best CEO.,2017-12-07 08:42:00-05:00,SAGE,positive
1113055.0,SAGE Therapeutics Shares Up 50.4% After the Company's Phase 2 Trial Met its Primary Endpoint,2017-12-07 07:30:00-05:00,SAGE,positive
1113056.0,Sage Therapeutics Announces Phase 2 Trial of SAGE-217 Met its Primary Endpoint,2017-12-07 06:07:00-05:00,SAGE,neutral
1113057.0,"Bank of America Maintains Buy on Sage Therapeutics, Lowers Price Target to $101.00",2017-11-16 09:34:00-05:00,SAGE,negative
1113058.0,Sage Therapeutics Announces $300M Offering Common Stock,2017-11-13 16:01:00-05:00,SAGE,neutral
1113059.0,"Canaccord Genuity Maintains Buy on Sage Therapeutics, Raises Price Target to $140.00",2017-11-13 12:46:00-05:00,SAGE,neutral
1113060.0,Chardan Capital Upgrades Sage Therapeutics to Buy,2017-11-10 08:36:00-05:00,SAGE,neutral
1113061.0,Adam Feuerstein Tweets: Updated: $SAGE drug reduces postpartum depression in two late-stage clinical trials statnews.com/2017/11/09/sag…,2017-11-09 10:20:00-05:00,SAGE,negative
1113062.0,"Adam Feuerstein Tweets: Gotta give $SAGE CEO Jeff Jonas, his team a lot of credit. Doubters scoffed at their CNS drug development strategy but it proved out today.",2017-11-09 08:48:00-05:00,SAGE,neutral
1113063.0,"Adam Feuerstein Tweets: Okay, maybe other stuff matters. $SAGE Jonas notes brexanolone effect consistent and meaningful across all studies. Placebo was variable.",2017-11-09 08:21:00-05:00,SAGE,positive
1113064.0,Sage Therapeutics Reports Brexanolone Achieved Primary Endpoints In Both Phase 3 Trials In Postpartum Depression,2017-11-09 06:10:00-05:00,SAGE,negative
1113065.0,"Sage Therapeutics Q3 EPS $(1.97) vs $(1.97) Est., No Sales",2017-11-02 08:46:00-04:00,SAGE,negative
1113066.0,RBC Initiated Coverage On 33 Pharma/Biotech Cos.,2017-09-15 07:38:00-04:00,SAGE,neutral
1113067.0,"Morgan Stanley Healthcare Conference Concludes Today, Presenters Include Ironwood Pharmaceuticals, Sage Therapeutics, Pfizer, TherapeuticsMD, Alnylam, bluebird bio, and Cigna",2017-09-13 09:24:00-04:00,SAGE,neutral
1113068.0,Sage Therapeutics Phase 3 STATUS Trial of Brexalonone in Super-Refractory Status Epilepticus Did Not Meet its Primary Endpoint,2017-09-12 06:01:00-04:00,SAGE,neutral
1113069.0,"Stifel Nicolaus Initiates Coverage On Sage Therapeutics with Buy Rating, Announces $104.00 Price Target",2017-08-09 07:30:00-04:00,SAGE,neutral
1113070.0,Sage Therapeutics Reports Q2 Loss/Share $(1.88) vs. $(1.67) Est.,2017-08-03 17:24:00-04:00,SAGE,neutral
1113071.0,"Goldman Sachs Global Healthcare Conference Continues Today, Presenters Include: Agilent, Sage Therapeutics, and GW Pharmaceuticals",2017-06-14 07:58:00-04:00,SAGE,neutral
1113072.0,Sage Therapeutics Reports Received Fast Track Designation for SAGE-217 for Treatment of Major Depressive Disorder,2017-05-18 07:18:00-04:00,SAGE,negative
1113073.0,"Needham Initiates Coverage On Sage Therapeutics with Buy Rating, Announces $82.00 Price Target",2017-05-16 07:40:00-04:00,SAGE,neutral
1113074.0,"TheStreet's Adam Feuerstein Tweets '$SAGE says '217 showed enough ""signal of activity"" in Parkinson's to move forward. Reading data, I have no idea if that's bullshit or not.'",2017-05-09 16:14:00-04:00,SAGE,negative
1113075.0,Sage Therapeutics Reports Q1 EPS $(1.52) vs $(1.61) Est.,2017-05-09 16:13:00-04:00,SAGE,neutral
1113076.0,"Adam Feuerstein TWeets: ""Right now, I don't plan on it taking longer,"" than 1H, which is why SRSE study results guidance remains same, Jonas told me. $SAGE",2017-04-13 15:54:00-04:00,SAGE,neutral
1113077.0,"Adam Feuerstein Tweets: However, Jonas says still working thru ""complexities"" of how to unblind/report SRSE data, leaving open possibility it takes more time. $SAGE",2017-04-13 15:52:00-04:00,SAGE,neutral
1113078.0,"Adam Feuerstein Tweets: $SAGE weak on Cowen note speculating SRSE ph3 results possibly pushed out to Q3. 

CEO Jonas (to me): No change in timing guidance, still 1H",2017-04-13 15:49:00-04:00,SAGE,negative
1113079.0,"Adam Feuerstein Tweets: $SAGE Leerink incrementally more bullish on PPD and MMD programs. The ""new"" bull thesis downplays looming SSRE ph3 outcome.",2017-03-23 07:24:00-04:00,SAGE,negative
1113080.0,"Sage Therapeutics Q4 EPS $(1.50) vs $(1.19) Est, No Revenue",2017-02-23 06:34:00-05:00,SAGE,negative
1113081.0,H.C. Wainwright Downgrades Sage Therapeutics to Neutral,2017-02-22 07:27:00-05:00,SAGE,neutral
1113082.0,"SunTrust Says Sage Would Be Good Takeout Target, But Believes An Acquiring Party  May Choose To Wait For Top-Line Data Readout From Phase 3 SAGE-547 Trial",2017-02-16 15:52:00-05:00,SAGE,positive
1113083.0,"Sage CEO On Bloomberg Interview Says ""We're on top of everyone's M&A list'",2017-02-16 15:24:00-05:00,SAGE,positive
1113084.0,Hearing Sage CEO Says Company Has Received Takeover Interest,2017-02-16 15:20:00-05:00,SAGE,positive
1113085.0,"Sage Shares Spiking Higher To High Of ~$65, Up 8.84% On Day",2017-02-16 15:19:00-05:00,SAGE,positive
1113086.0,Sage Therapeutics Advances Sage-217 To Phase 2 In Major Depressive Disorder On Positive Signal Of Activity And Tolerability,2017-02-13 07:09:00-05:00,SAGE,negative
1113087.0,Sage Therapeutics Initiates Phase 2 Clinical Development for SAGE-217 in Mood Disorders,2016-12-19 07:09:00-05:00,SAGE,neutral
1113088.0,"Raymond James Upgrades Sage Therapeutics to Strong Buy, Announces $84.00 Target",2016-12-14 07:45:00-05:00,SAGE,positive
1113089.0,"Stifel Nicolaus Initiates Coverage On Sage Therapeutics, Inc. - Common Stock at Buy, Announces $90.00",2016-11-14 06:38:00-05:00,SAGE,neutral
1113090.0,"Leerink Swann Assumes Sage Therapeutics at Outperform, Announces $68.00 PT",2016-10-04 07:13:00-04:00,SAGE,neutral
1113091.0,Raymond James Initiates Coverage on Sage Therapeutics at Outperform,2016-09-13 04:25:00-04:00,SAGE,neutral
1113092.0,BMO Capital Initiates Coverage on Sage Therapeutics at Outperform,2016-06-29 06:27:00-04:00,SAGE,neutral
1113093.0,"H.C. Wainwright Initiates Coverage on Sage Therapeutics at Buy, Announces $56.00 PT",2016-06-23 07:06:00-04:00,SAGE,neutral
1113094.0,Chardan Capital Initiates Coverage on Sage Therapeutics at Sell,2016-05-24 08:34:00-04:00,SAGE,neutral
1113095.0,"Chardan Capital Initiates Coverage on Sage Therapeutics at Sell, Announces $18.00 PT",2016-05-24 06:21:00-04:00,SAGE,neutral
1113096.0,"Goldman Sachs Initiates Coverage on Sage Therapeutics at Neutral, Announces $83.00 PT",2016-03-30 06:45:00-04:00,SAGE,neutral
1113097.0,"Lake Street Capital Initiates Coverage on Sage Therapeutics at Buy, Announces $90.00 PT",2016-03-11 08:54:00-05:00,SAGE,neutral
1113098.0,Sage Therapeutics Prices ~3.157M Share Offering @$47.50/Share,2016-01-07 04:11:00-05:00,SAGE,positive
1113099.0,SAGE Therapeutics Announces Results from Successful Exploratory Trial in Essential Tremor,2015-09-03 06:01:00-04:00,SAGE,positive
1113100.0,SAGE Receives Special Protocol Assessment for Phase 3 STAT-Refractory Status EpileUS Trial of SAGE-547 in Superpticus,2015-08-06 06:33:00-04:00,SAGE,positive
1113101.0,SAGE Therapeutics Achieves 77% Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in SRSE,2015-05-14 06:24:00-04:00,SAGE,neutral
1113102.0,SAGE Therapeutics Prices ~2.285M Share Offering @$52.50/Share,2015-04-15 04:54:00-04:00,SAGE,positive
1113103.0,"SunTrust Robinson Humphrey Initiates Coverage on Sage Therapeutics at Buy, Announces $67.00 PT",2015-01-27 06:27:00-05:00,SAGE,neutral
1113104.0,Sage Therapeutics Reports Q3 EPS of $(0.50) vs $(0.40) Est,2014-11-11 06:34:00-05:00,SAGE,neutral
1113105.0,"SSage Therapeutics Reports SGAE-547 Met Primary, Secondary Efficacy and Safety Endpoints",2014-11-10 06:31:00-05:00,SAGE,positive
1113106.0,SAGE Therapeutics Announces Six Abstracts Accepted for Poster Presentations at Neuroscience 2014,2014-11-07 06:34:00-05:00,SAGE,positive
1113107.0,Goldman Sachs Raise Sage Therapeutics ,2014-09-24 05:48:00-04:00,SAGE,neutral
1113108.0,SAGE Therapeutics Names Michael F. Cola to Board of Directors ,2014-09-16 06:32:00-04:00,SAGE,neutral
1113109.0,SAGE Therapeutics Presents Positive Preclinical Data on SAGE-217,2014-09-02 06:31:00-04:00,SAGE,positive
1113110.0,Sage Therapeutics Reports Q2 EPS of $(4.57) Which May Not Compare $(1.23) Est,2014-08-14 06:19:00-04:00,SAGE,neutral
1113111.0,"Leerink Swann Initiates Coverage on Sage Therapeutics at Outperform, Announces $46.00 PT",2014-08-12 09:18:00-04:00,SAGE,neutral
1113112.0,"Goldman Sachs Initiates Coverage on Sage Therapeutics at Neutral, Announces $38.00 PT",2014-08-12 09:17:00-04:00,SAGE,neutral
1113113.0,"Canaccord Genuity Initiates Coverage on Sage Therapeutics at Buy, Announces $40.00 PT",2014-08-12 06:43:00-04:00,SAGE,neutral
1113114.0,"JP Morgan Initiates Coverage on Sage Therapeutics at Overweight, Announces $42.00 PT",2014-08-12 06:28:00-04:00,SAGE,neutral
1113115.0,"Canaccord Genuity Initiates Coverage on Sage Therapeutics at Buy, Announces $40.00 PT",2014-08-12 06:28:00-04:00,SAGE,neutral
1113116.0,SAGE Therapeutics Prices 5M Share IPO at $18.00/Share,2014-07-17 18:57:00-04:00,SAGE,positive
1113117.0,Are Michael Vick and Other Celebrities Involved with a Pump and Dump?,2011-10-07 14:26:00-04:00,SAGE,negative
1113118.0,Sagebrush Gold Receives Negative Mention by Shortseller,2011-10-07 12:45:00-04:00,SAGE,negative
